178 related articles for article (PubMed ID: 37780115)
1. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up.
Adlany YK; Šošić L; Senti G; Lang CCV; Wüthrich B; Kündig TM; Johansen P
J Allergy Clin Immunol Glob; 2023 Feb; 2(1):43-50. PubMed ID: 37780115
[TBL] [Abstract][Full Text] [Related]
2. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
3. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Safety, Efficacy, and Compliance of Intralymphatic Immunotherapy for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis.
Wang W; Wang X; Wang H; Wang X
Int Arch Allergy Immunol; 2023; 184(8):754-766. PubMed ID: 37105134
[TBL] [Abstract][Full Text] [Related]
5. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy.
Weinfeld D; Westin U; Hellkvist L; Mellqvist UH; Jacobsson I; Cardell LO
Allergy Asthma Clin Immunol; 2020; 16():31. PubMed ID: 32368217
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of cervical intralymphatic immunotherapy for house dust mite allergic rhinitis: A pilot study.
Wang K; Zheng R; Chen Y; Yu Q; Zhong H; Xiao P; Wang Y; Tang J
Am J Otolaryngol; 2019; 40(6):102280. PubMed ID: 31519431
[TBL] [Abstract][Full Text] [Related]
7. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
[TBL] [Abstract][Full Text] [Related]
8. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
Hjalmarsson E; Hellkvist L; Karlsson A; Winquist O; Kumlien Georén S; Westin U; Cardell LO
J Investig Allergol Clin Immunol; 2023 Oct; 33(5):362-372. PubMed ID: 37843385
[TBL] [Abstract][Full Text] [Related]
9. Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis.
Khoshkhui M; Jabbari F; Shafiee Zargar F; Motavalli Haghi N; Ariaee N
Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):149-157. PubMed ID: 38822510
[TBL] [Abstract][Full Text] [Related]
10. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase.
Hellkvist L; Hjalmarsson E; Weinfeld D; Dahl Å; Karlsson A; Westman M; Lundkvist K; Winqvist O; Georén SK; Westin U; Cardell LO
Allergy; 2022 Mar; 77(3):883-896. PubMed ID: 34379802
[TBL] [Abstract][Full Text] [Related]
11. Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy.
Chabot A; Lang C; Kündig TM; Schmid-Grendelmeier P; Johansen P
Int Arch Allergy Immunol; 2023; 184(10):985-993. PubMed ID: 37467738
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
van Amersfort K; Vernooij JCM; van der Lee A
Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
[TBL] [Abstract][Full Text] [Related]
14. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study.
Schmid JM; Nezam H; Madsen HH; Schmitz A; Hoffmann HJ
Clin Transl Allergy; 2016; 6():19. PubMed ID: 27231527
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies.
Lee SP; Choi SJ; Joe E; Lee SM; Lee MW; Shim JW; Kim YJ; Kyung SY; Park JW; Jeong SH; Jung JH
Allergy Asthma Immunol Res; 2017 May; 9(3):272-277. PubMed ID: 28293934
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
17. Novel strategies for the treatment of grass pollen-induced allergic rhinitis.
Larsson O; Hellkvist L; Peterson-Westin U; Cardell LO
Expert Opin Biol Ther; 2016 Sep; 16(9):1143-50. PubMed ID: 27269991
[TBL] [Abstract][Full Text] [Related]
18. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
19. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic immunotherapy.
Senti G; Johansen P; Kündig TM
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):537-43. PubMed ID: 19680119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
